CN106138217A - Fructus Mori granule prevents and treats the application in diabetes and complication medicine thereof in preparation - Google Patents
Fructus Mori granule prevents and treats the application in diabetes and complication medicine thereof in preparation Download PDFInfo
- Publication number
- CN106138217A CN106138217A CN201610643249.3A CN201610643249A CN106138217A CN 106138217 A CN106138217 A CN 106138217A CN 201610643249 A CN201610643249 A CN 201610643249A CN 106138217 A CN106138217 A CN 106138217A
- Authority
- CN
- China
- Prior art keywords
- application
- diabetes
- myocardial
- myocardial ischemia
- complication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to Fructus Mori granule and prevent and treat the application in diabetes and complication medicine thereof in preparation, wherein, described complication is the one in cardiovascular disease, cerebrovascular disease, injury of kidney, blood vessel injury, and Fructus Mori granule especially has good prevention effect to diabetes complicated cardiovascular disease；Described cardiovascular disease is myocardial ischemia, and cardiac disorder, myocardial damage or myocardial infarction that myocardial ischemia is especially caused by Fructus Mori granule have prominent curative effect.Mulberry particles can effectively control blood glucose and blood lipid level in diabetes patient's body, can improve diabetes and merge the cardiac disorder that causes of myocardial ischemia, can effectively inhibited oxidation stress.
Description
Technical field
The present invention relates to pharmaceutical technology field, particularly relate to Fructus Mori granule and prevent and treat diabetes and complication medicine thereof in preparation
In application.
Background technology
Fructus Mori, has another name called Fructus Mori, sorosis, Semen Mori, is the fruit of Moraceae Morus mulberry (Morus alba L.) plant
Real, the ripe fresh fruit taste sweet juice of Fructus Mori is many, is one of fruit of often eating of people.This platymiscium whole world there are about 16 kinds, is distributed in north
Temperate zone, Tropical Asian and the torrid zone, Africa and area, America.China there are about 11 kinds, is distributed in whole nation most area, with Jiangsu, Zhejiang
Sericulture area, the south such as river yield is bigger.Containing abundant saccharide, organic acid, lipid, vitamin, pigment, non-pigmented in Fructus Mori
Phenol and mineral matter and other components.In terms of drug effect, Fructus Mori is sweet in flavor and cold in property, have the liver and the kidney tonifying, promote the production of body fluid moisturize, the merit such as black hair improving eyesight
Effect.Chlorogenic acid is the organic acid that wherein content is higher, and it has pharmacological action widely, the most 1. cardiovascular protective effect simultaneously；②
Antimutagenic and antitumaous effect；The most antibacterial and antivirus action；4. effect for reducing fat；5. leukemia resisting action；6. immunoregulation effect
Deng.In modern Chinese medicine, Fructus Mori is generally processed into mulberry particles.
Although its complication is had certain effect while treatment diabetes by some chemicals the most clinical, but because of
Its effect is excessively strong, makes internal blood sugar level change greatly, and easily increases the weight of the vitals damages such as heart and brain, so seeking in Chinese medicine
Looking for the property of medicine gentle, the medicine of persistent is extremely urgent.
Summary of the invention
First purpose of the present invention is to provide mulberry particles application in preparation preventing and treating diabetes medicament.
Second object of the present invention is to provide Fructus Mori granule and prevents and treats answering in diabetes and complication medicine thereof in preparation
With.
Wherein, described diabetes are I type or type ii diabetes.
Wherein, the one during described complication is cardiovascular disease, cerebrovascular disease, injury of kidney, blood vessel injury.
Wherein, described complication is cardiovascular disease.
Wherein, described cardiovascular disease is arrhythmia, myocardial fibrosis, coronary heart diseases and angina pectoris, heart failure, hyperemia
DHF, myocardial ischemia, myocardial ischemia-reperfusion, myocarditis, atherosclerosis, peripheral tissues's organ or extremity lack
One in histoorgan acute and chronic trauma, imbalance or indirect sequelae that blood, shock, ischemia or Reperfu-sion cause.
Wherein, described cardiovascular disease is myocardial ischemia.
Wherein, described cardiovascular disease is cardiac disorder, myocardial damage or the myocardial infarction that myocardial ischemia causes.
Wherein, described cardiovascular disease is the cardiac disorder that myocardial ischemia causes.
Wherein, described cerebrovascular disease is cerebral ischemia.
Fructus Mori granule of the present invention is with Fructus Mori as active component, use pelletize means known in this field preparation and
Become.
Preferably, Fructus Mori granule of the present invention is prepared via a method which to obtain:
Take Fructus Mori, with soak by water 1-3 time, each 1-3h, merge decoction liquor, filter, take filtrate and be condensed into thick paste, pelletize,
Obtain.
In granulation process, pharmaceutic adjuvant commonly used in the art can be added.
Those skilled in the art know, and with the Fructus Mori granule that is prepared from as raw material, use conventional preparation process, individually
Use or prepare into the various different dosage forms that can use clinically with other drug, as powder, pill, capsule,
The oral preparations such as tablet, microcapsule, soft capsule, electuary.
The present invention determines various dose group (low dose group 10mg/kg/day, middle dosage group 20mg/kg/day, high dose
Group 30mg/kg/day) mulberry particles on blood glucose, blood fat and the impact of insulin content in C57BL/6 diabetic mice body, find
It can substantially reduce diabetic mice hyperglycemia and elevated blood lipid levels, rises high insulin levels, and has certain dose-dependant
Effect.
Further, diabetic mice makes myocardial ischemia-reperfusion model, determines mulberry particles to cardiac function
Parameter and the impact of myocardial enzymes, find that it can improve the cardiac myocyte dysfunction that myocardial ischemia-reperfusion causes, reduce the heart
Flesh infarct size, reduces in serum the myocardium enzyme such as LDH and CK-MB and expresses, and have certain dose-dependent effect.
In order to be further elucidated with its mechanism of action, determine oxidative damage parameters in serum (MDA) and antioxidase (GSH,
SOD, CAT and GR) level, find that it can effectively reduce MDA level, alleviate lipid peroxidation situation, and it was found that it is permissible
GSH, SOD, CAT and the GR level of rising, tackles oxidative damage.
The Fructus Mori granule of the present invention can effectively control blood glucose and blood lipid level in diabetes body, can improve diabetes and close
And the cardiac disorder that myocardial ischemia causes, Fructus Mori granule can effectively inhibited oxidation stress.
Accompanying drawing explanation
Fig. 1 is the impact knot of Fructus Mori Granules on Mouse fasting glucose, Fasting insulin level and insulin sensitivity index
Fruit figure；
Fig. 2 is that mulberry particles is to mice triglyceride, T-CHOL, low density lipoprotein, LDL and hdl level
Affect result figure；
Fig. 3 is mulberry particles on diabetes merge myocardial ischemia-reperfusion mouse core functional parameter affect result figure；
Fig. 4 is that mulberry particles merges myocardial ischemia-reperfusion murine myocardial infarction area and the shadow of myocardial enzymes to diabetes
Ring result figure；
Fig. 5 is mulberry particles on diabetes merge antioxidant enzyme levels in myocardial ischemia-reperfusion Mice Body affect result
Figure.
Detailed description of the invention
Following example are used for illustrating the present invention, but are not limited to the scope of the present invention.The examination related in embodiment
Agent or raw material are known product, commercially available acquisition.The Fructus Mori granule related to, is prepared via a method which to obtain: take Fructus Mori
500g, boiling 2 times, each 2h, merge decoction liquor, filter, filtrate is condensed into thick paste, pelletizes, to obtain final product.
The impact on diabetes glucose, blood fat and insulin level of embodiment 1 mulberry particles
Mulberry particles, is provided by Shaanxi Junbisha Pharmaceutical Co., Ltd..Used time becomes desired concn with normal saline.Examination
Testing animal is male C57BL/6 mice, and non-inbred line closed colony, body weight 23-25g, by The Fourth Military Medical University's Experimental Animal Center
There is provided.Laboratory room temperature 20-22 DEG C, relative humidity 40%-60%, ventilation fan ventilation, lamp 12h/ day, raise in cages, every cage 8
Only, within every three days, cage is cleaned once.
Diabetes mice model: the C57BL/6 mice that grows up is randomly divided into normal group and diabetic groups, often 10 mices of group；
Normal group feeds chow diet, and diabetic groups feeds high lipid food.After feeding three weeks, fasting 12 hours, diabetic groups lumbar injection chain
Urea assistant rhzomorph (STZ, 50mg/kg), normal group injection 0.1mol/L citrate buffer, normal group continues to feed chow diet, sugar
Urine disease group feed high-sugar-fat-diet, after surrounding, measure mouse blood sugar level, concentration > 11.1mM i.e. think model success.
Mice after modeling success is divided into 3 groups, and respectively low dose group, middle dosage group and high dose group, often group 6 is little
Mus, wherein, three groups of dosages are respectively as follows: low dose group 10mg/kg/day, middle dosage group 20mg/kg/day, high dose group
30mg/kg/day；Administration time: surrounding.After last administration, measure mouse blood sugar, insulin, lipid level.
Mulberry particles affects result to blood glucose and insulin and sees Fig. 1；Mulberry particles affects result to lipid level and sees Fig. 2.
In Fig. 1, Control: normal group；Model group: diabetic groups；Compared with control group: ##P ＜ 0.01；With
Model group is compared: * P ＜ 0.05, * * P ＜ 0.01.
In Fig. 2, TG: triglyceride；TC: T-CHOL；LDL-c: low density lipoprotein, LDL；HDL-c: high density lipoprotein；
Control: normal group；Model group: diabetic groups；Compared with control group: ##P ＜ 0.01；Compared with model group: * P ＜
0.05, * * P ＜ 0.01.
Embodiment 2: mulberry particles merges the effect of myocardial ischemia reperfusion injury to diabetes
Mulberry particles, is provided by Shaanxi Junbisha Pharmaceutical Co., Ltd..Used time becomes desired concn with normal saline.Examination
Testing animal is male C57BL/6 diabetic mice, non-inbred line closed colony, body weight 23-25g, dynamic by The Fourth Military Medical University's experiment
Thing center provides.Laboratory room temperature 20-22 DEG C, relative humidity 40%-60%, ventilation fan ventilation, lamp 12h/ day, cage
Support, 8, every cage, within every three days, clean cage once.
Diabetes merge myocardial ischemia-reperfusion model: after lumbar injection 75mg/kg Patients Under Ketamine Anesthesia mice, by mice
Dorsal position fixes on Mus plate, cuts off downrights, makees a longitudinal cut being about 0.5cm at midline position, and then pausing property is divided
From fascia and muscle, cause trachea to expose, insert the tracheal casing pipe being suitable for, determine that tracheal intubation connects toy breathing after unobstructed
Machine, tidal volume controls at 250-300ml/min, and respiratory frequency is 114 beats/min, and respiratory quotient is 1.5: 1.One is made on the right side of cervical region
About 0.5cm size otch, blunt separation subcutaneous tissue, expose jugular vein, insert the venous detaining needle that a size is 24G, and liver
Elementization is standby.Front field of operation preserved skin unhairing, the nearly center line of left breast makees an oblique type otch being about 1.0cm, then blunt separation breast
The muscle in portion, separates the 4th or the 5th Intercostal muscle, pulls open intercostal space with drag hook and to use eye speculum to strut fixing, cut off the heart
Bag makes exposure heart, and emphasis exposes the great cardiac vein between left auricle and pulmonary conus, with this vein for mark, at left auricle
With noinvasive little round needle 8-0 silk thread through cardiac muscle top layer at the about 2mm of lower section, in pulmonary conus branch pin.Ischemia/reperfusion model
Using ejector sleeve method, will pass through the silk thread two ends of cardiac muscle from the polyethylene tube of a caliber about 2mm, ejector sleeve compressing cardiac muscle causes
Left main coronary occlusion forms myocardial ischemia, unclamps silk thread, Reperfu-sion 24h after 30min.While experiment starts, respectively will
Needle electrode inserts mice extremity subcutaneous monitoring II lead electrocardiogram, occurs that ST section raises more than 0.2mV, the corresponding portion of heart surface
Position primary colors loses color and ischemia success is described, after LAD reopens, when ST section rapid drawdown, heart surface is become scarlet mark from pale
Reperfu-sion success.Sham operated rats (sham group) threading and do not tighten up line, observing time is identical with ischemia 30min group.
After modeling success, mice is divided into 3 groups, respectively low dose group, middle dosage group and high dose group, this experimental administration
Dosage is respectively as follows: low dose group 10mg/kg/day, middle dosage group 20mg/kg/day, high dose group 30mg/kg/day；During administration
Between: surrounding.After last administration, measure cardiac functional parameter, myocardial infarct size, myocardial enzymes and antioxidase.
The result that affects of cardiac functional parameter is shown in Fig. 3 by mulberry particles；Mulberry particles is to myocardial infarct size and the shadow of myocardial enzymes
Ring result and see Fig. 4；Mulberry particles affects result to internal antioxidase and sees Fig. 5.
In Fig. 3, Sham: normal group；I/R group: diabetes merge myocardial ischemia-reperfusion group；Compared with sham group: ##P ＜
0.01；Compared with I/R group: * P ＜ 0.05, * * P ＜ 0.01；
In Fig. 4, Sham: normal group；I/R group: diabetes merge myocardial ischemia-reperfusion group；Compared with sham group: ##P ＜
0.01；Compared with I/R group: * P ＜ 0.05, * * P ＜ 0.01.
In Fig. 5, Sham: normal group；I/R group: diabetes merge myocardial ischemia-reperfusion group；Compared with sham group: ##P ＜
0.01；Compared with I/R group: * P ＜ 0.05, * * P ＜ 0.01.
The results show: mulberry particles can effectively control blood glucose in Mice Body, blood fat and insulin level；Fructus Mori
Granule can effectively be stablized diabetes and merge the cardiac disorder that myocardial ischemia-reperfusion mice causes；Mulberry particles can have
The diabetes that alleviate of effect merge the myocardial damage that myocardial ischemia-reperfusion mice causes；Mulberry particles can be with significantly raised diabetes
Merge antioxidant enzyme levels in myocardial ischemia-reperfusion Mice Body.
Although, used general explanation, detailed description of the invention and test, the present invention made detailed retouching
Stating, but on the basis of the present invention, can make some modifications or improvements it, this is apparent to those skilled in the art
's.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed
Scope.
Claims (10)
1. mulberry particles application in preparation preventing and treating diabetes medicament.
2. mulberry particles prevents and treats the application in diabetes and complication medicine thereof in preparation.
Application the most according to claim 2, it is characterised in that: described complication is cardiovascular disease, cerebrovascular disease, kidney
One in damage, blood vessel injury.
Application the most according to claim 3, it is characterised in that: described complication is cardiovascular disease.
5. according to the application described in claim 3 or 4, it is characterised in that: described cardiovascular disease is arrhythmia, ventricular fiber
Change, coronary heart diseases and angina pectoris, heart failure, congestive heart failure, myocardial ischemia, myocardial ischemia-reperfusion, myocarditis, tremulous pulse
Histoorgan acute and chronic trauma that atherosis, peripheral tissues's organ or limb ischemia, shock, ischemia or Reperfu-sion cause, mistake
One in tune or indirect sequelae.
Application the most according to claim 5, it is characterised in that: described cardiovascular disease is myocardial ischemia.
Application the most according to claim 6, it is characterised in that: described complication is that the cardiac function that myocardial ischemia causes is disorderly
Disorderly, myocardial damage or myocardial infarction.
Application the most according to claim 7, it is characterised in that: described complication is that the cardiac function that myocardial ischemia causes is disorderly
Disorderly.
Application the most according to claim 3, it is characterised in that: described cerebrovascular disease is cerebral ischemia.
10. according to the application described in any one of claim 1-9, it is characterised in that: described mulberry particles is made by the following method
Standby obtain: take Fructus Mori, with soak by water 1-3 time, each 1-3h, merge decoction liquor, filter, take filtrate and be condensed into thick paste, granulation, i.e.
?.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610643249.3A CN106138217B9 (en) | 2016-08-08 | 2016-08-08 | Application of mulberry particles in preparation of medicine for preventing and treating diabetes and complications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610643249.3A CN106138217B9 (en) | 2016-08-08 | 2016-08-08 | Application of mulberry particles in preparation of medicine for preventing and treating diabetes and complications thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| CN106138217A true CN106138217A (en) | 2016-11-23 |
| CN106138217B CN106138217B (en) | 2020-06-26 |
| CN106138217B9 CN106138217B9 (en) | 2020-08-25 |
Family
ID=57328745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610643249.3A Active CN106138217B9 (en) | 2016-08-08 | 2016-08-08 | Application of mulberry particles in preparation of medicine for preventing and treating diabetes and complications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138217B9 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112870278A (en) * | 2021-03-30 | 2021-06-01 | 镇江璐微科技咨询有限责任公司 | Composition for treating diabetes based on mulberry extract PMV3281 and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1338275A (en) * | 2001-06-29 | 2002-03-06 | 上海复旦张江生物医药股份有限公司 | Chinese-medicinal extract with alpha-glucosidase inhibitor activity, and its preparing process and application |
| CN1463734A (en) * | 2002-06-13 | 2003-12-31 | 王宏 | A prepared Chinese medicine for treating diabetes mellitus and method for preparing same |
| CN101125139A (en) * | 2007-09-28 | 2008-02-20 | 天津市尖峰天然产物研究开发有限公司 | Application of procyanidin B2 in preparing medicine for preventing and treating diabetes and vascular complication |
| CN103610750A (en) * | 2013-11-07 | 2014-03-05 | 李刚 | Method for extracting, separating and purifying glucosidase inhibitor |
| CN104189088A (en) * | 2014-08-13 | 2014-12-10 | 河南中医学院 | Application of mulberry fruit extract in preparation of hypoglycaemic agent |
| CN104434940A (en) * | 2014-12-02 | 2015-03-25 | 中国人民解放军第四军医大学 | Application of panax japonicus IV a in prevention and treatment of cardiovascular disease and complication of cardiovascular disease |
-
2016
- 2016-08-08 CN CN201610643249.3A patent/CN106138217B9/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1338275A (en) * | 2001-06-29 | 2002-03-06 | 上海复旦张江生物医药股份有限公司 | Chinese-medicinal extract with alpha-glucosidase inhibitor activity, and its preparing process and application |
| CN1463734A (en) * | 2002-06-13 | 2003-12-31 | 王宏 | A prepared Chinese medicine for treating diabetes mellitus and method for preparing same |
| CN101125139A (en) * | 2007-09-28 | 2008-02-20 | 天津市尖峰天然产物研究开发有限公司 | Application of procyanidin B2 in preparing medicine for preventing and treating diabetes and vascular complication |
| CN103610750A (en) * | 2013-11-07 | 2014-03-05 | 李刚 | Method for extracting, separating and purifying glucosidase inhibitor |
| CN104189088A (en) * | 2014-08-13 | 2014-12-10 | 河南中医学院 | Application of mulberry fruit extract in preparation of hypoglycaemic agent |
| CN104434940A (en) * | 2014-12-02 | 2015-03-25 | 中国人民解放军第四军医大学 | Application of panax japonicus IV a in prevention and treatment of cardiovascular disease and complication of cardiovascular disease |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112870278A (en) * | 2021-03-30 | 2021-06-01 | 镇江璐微科技咨询有限责任公司 | Composition for treating diabetes based on mulberry extract PMV3281 and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106138217B (en) | 2020-06-26 |
| CN106138217B9 (en) | 2020-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019076066A1 (en) | Bitter ganoderma lucidum spore powder and preparation method thereof | |
| CN104225217B (en) | A kind of Chinese medicine preparation for treating coronary heart disease and preparation method thereof | |
| CN105360300A (en) | Blood-glucose-reducing yogurt and preparation method of the blood-glucose-reducing yogurt | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN102048821A (en) | Method for preparing perhexiline pharmaceutical preparation | |
| KR20140034620A (en) | Composition for preventing or treating diabetbes mellitus disease containing extract of plants | |
| CN106138217A (en) | Fructus Mori granule prevents and treats the application in diabetes and complication medicine thereof in preparation | |
| CN102885914B (en) | Traditional Chinese medicine oral liquid for treating chicken coccidiasis and preparation method thereof | |
| CN108570116B (en) | Pleurotus citrinopileatus polysaccharide, preparation method and medical application in preventing and treating diabetes | |
| CN103719864A (en) | Blood glucose-reducing natto combined capsule and preparation method thereof | |
| CN103919939A (en) | Application of japanese banana stem and leaf extract to preparation of medicament for treating or preventing diabetes | |
| CN106668348A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
| CN105963337A (en) | Vaccinium bracteatum thunb extract and application thereof | |
| JP2016504414A (en) | Pharmaceutical composition and health functional food composition for prevention or treatment of diabetic complications or angioedema comprising natural extract | |
| KR0165939B1 (en) | Pharmaceutical compositions containing the extracts of lycil fructus for blood glucose reducing agent and the process for preparing them | |
| CN107875350B (en) | A Chinese medicinal composition for treating diabetes | |
| CN101856357B (en) | Application of rotundic acid in preparing medicines for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN104434940A (en) | Application of panax japonicus IV a in prevention and treatment of cardiovascular disease and complication of cardiovascular disease | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| CN107982264A (en) | A kind of drug regimen for preventing animal echinococcosis and its application | |
| CN109432377A (en) | Its green onion Bulbus Allii Fistulosi extract activates yang the preparation method of patch | |
| CN1291727C (en) | Chinese medicinal composition for treating cardiovascular disease, preparation and use thereof | |
| CN1788753A (en) | General glycoside extract from tree peony root bark and its preparation method and uses thereof | |
| AU2020101850A4 (en) | A pharmaceutical composition for the treatment of diabetes | |
| CN106727943A (en) | One kind treats phthisical pharmaceutical composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CI03 | Correction of invention patent | ||
| CI03 | Correction of invention patent |
Correction item: Denomination of Invention|Abstract|Claims|Description Correct: Application of mulberry granules in the preparation of drugs for prevention and treatment of diabetes mellitus and its complications|Correct False: Application of mulberry granules in the preparation of drugs for prevention and treatment of diabetes and its complications|error Number: 26-02 Page: ?? Volume: 36 Correction item: Denomination of Invention Correct: Application of mulberry granules in the preparation of drugs for prevention and treatment of diabetes mellitus and its complications False: Application of mulberry granules in the preparation of drugs for prevention and treatment of diabetes and its complications Number: 26-02 Volume: 36 |